The ulcerative colitis (UC) market is expected to grow steadily over the next decade. The entry of first-in-UC oral therapies (e.g., Pfizer’s Xeljanz) for the moderate to severe population, together with additional emerging agents with novel MOAs and a general increase in the use of biologics, will help to drive market growth. In particular, the availability of non-TNF biologics (e.g., Takeda’s Entyvio) expands physicians’ treatment armamentarium and intensifies market competition. In balance with these factors, the entry of generics for leading branded conventional agents (e.g., Shire’s Lialda), continuing generic erosion of other conventional agents, and additional entries/expanded uses of less expensive biosimilar TNF-alpha inhibitors (e.g., Pfizer’s Inflectra, Amgen’s Amjevita) will constrain the UC market. Indeed, emerging therapies looking to penetrate this market will need to be clearly differentiated from competitors.

QUESTIONS ANSWERED

  • What are the similarities and differences in how U.S., European, and Japanese gastroenterologists treat UC?
  • How do gastroenterologists perceive biosimilar agents, and what impact have/will these agents have on the UC market?
  • What are KOLs’ insights into current treatment options (e.g., AbbVie/Eisai’s Humira, Pfizer’s Xeljanz)? What factors drive their treatment decisions?
  • What are KOLs’ perceptions of key emerging therapies (e.g., AbbVie’s upadacitinib, Roche/Genentech’s etrolizumab, Janssen’s Stelara, Celgene’s ozanimod), and where do they see these agents fitting into the treatment algorithm?

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.


Related Reports

Ulcerative Colitis | Landscape & Forecast | Disease Landscape & Forecast

The ulcerative colitis (UC) market is expected to grow steadily over the next decade. The entry of first-in-UC oral...

View Details

Ulcerative Colitis | Unmet Need | Detailed, Expanded Analysis (US & EU)

The moderate to severe ulcerative colitis (UC) drug market still offers substantial opportunity for companies that can address the remaining unmet needs in...

View Details

Ulcerative Colitis | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US) - Pediatric

MARKET OUTLOOK Conventional therapies (5-ASAs, corticosteroids) are typically used to treat mild to moderate pediatric ulcerative co...

View Details

Ulcerative Colitis | Epidemiology | Extrapolated Worldwide Coverage

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key ulcerative colitis pat...

View Details